The case for equitable haemophilia care

Abstract

Access to clotting factor concentrates (CFCs) and their regular prophylactic use over the past two to three decades has transformed the lives of people with haemophilia in countries with access to these products. From a story of near universal musculoskeletal dysfunction and high mortality at a young age, survival of people with haemophilia and their quality of life has started to catch up with people without haemophilia in high-income countries (HICs). The development of recombinant CFCs in the mid-1990s made this progress possible, and it was anticipated that in the next one or two decades that these products would be sufficiently accessible at affordable costs to reach the same outcomes in the rest of the world.